@article {4089,
	title = {Application of long-circulating liposomes to cancer photodynamic therapy},
	journal = {Biological \& Pharmaceutical Bulletin},
	volume = {20},
	number = {6},
	year = {1997},
	note = {ISI Document Delivery No.: XG547Times Cited: 26Cited Reference Count: 30},
	month = {Jun},
	pages = {670-673},
	type = {Article},
	abstract = {Photodynamic therapy (PDT) as a cancer treatment is notable for its quite low side effects in comparison with those of chemotherapy and radiotherapy. However, the accumulation of porphyrin derivatives used in PDT into tumor tissues is rather low. Since long-circulating liposomes are known to accumulate passively into tumor tissues, we liposomalized a porphyrin derivative, benzoporphyrin derivative monoacid ring A (BPD-MA), and used these liposomes to investigate the usefulness of PDT for tumor-bearing mice. BPD-MA was liposomalized into glucuronate-modified liposomes, which are known to be long-circulating. These liposomes were injected i.v. into Balb/c mice bearing Meth A sarcoma, and tumor regression and survival time were monitored after irradiation with laser light. Tumor regression and complete curing of tumor (80\% cure rate by the treatment with 6 mg/kg BPD-R?IA) were observed when long circulating liposomalized BPD-MA was injected and laser-irradiated. In contrast, only a 20\% cure rate was obtained when the animals were treated with BPD-MA solution or BPD-MA entrapped in conventional liposomes. These results suggest that a long-circulating liposomal formulation of photo-sensitive agents is useful for PDT.},
	keywords = {BEARING MICE, benzoporphyrin, BENZOPORPHYRIN DERIVATIVES, BPD, CELLS, DERIVATIVE, drug delivery system, EFFICACY, INVIVO, LIPOPROTEINS, liposome, MURINE TUMOR-MODEL, PHOTODYNAMIC THERAPY, PHOTOSENSITIZER, time},
	isbn = {0918-6158},
	url = {<Go to ISI>://A1997XG54700016},
	author = {Oku, N. and Saito, N. and Namba, Y. and Tsukada, H. and Dolphin, D. and Okada, S.}
}
@article {3825,
	title = {Pyrrolic photosensitizers},
	journal = {Current Medicinal Chemistry},
	volume = {3},
	number = {4},
	year = {1996},
	note = {ISI Document Delivery No.: VE317Times Cited: 21Cited Reference Count: 172},
	month = {Aug},
	pages = {239-272},
	type = {Review},
	abstract = {There are three major classes of photosensitizers which can initiate a phototoxic effect to tissues upon irradiation. These are the cationic dyes (Type I Photosensitizer), the psoralens (Type I and II Photosensitizer), and cyclic polypyrrolic compounds (Type II Photosensitizer). The polypyrrolic compounds such as porphyrins have been investigated since the late 1800{\textquoteright}s for their ability to destroy tissue. In the last ten years, compounds such as chlorins and expanded porphyrins have begun to dominate the preclinical field because they can be activated with light at wavelengths tissue does not effectively absorb. The results of these investigation have been reported in more than 10,000 papers in the field covering aspects from mechanisms of action, photophysics, structure activity relationships, new compound development and clinical investigations. With the approval of PHOTOFRIN(R), (porfimer sodium), the first of the pyrrolic compounds to win acceptance by international regulatory bodies and with nearly 10 other second generation compounds undergoing early clinical trials for diseases ranging from esophageal and skin cancers to age related macular degeneration, the field of photodynamic therapy would seem to have a bright future.},
	keywords = {BENZOPORPHYRIN DERIVATIVES, capillary electrophoresis, ENDOGENOUS, M-THPC, MOUSE-TUMOR MODEL, PHOTODYNAMIC THERAPY, PHOTOFRIN-II, PLASMA-LIPOPROTEINS, PROTOPORPHYRIN, RING-A BPD, TISSUE DISTRIBUTION},
	isbn = {0929-8673},
	url = {<Go to ISI>://A1996VE31700002},
	author = {Sternberg, E. and Dolphin, D.}
}
@article {3017,
	title = {1993 SYNTEX-AWARD LECTURE - PHOTOMEDICINE AND PHOTODYNAMIC THERAPY},
	journal = {Canadian Journal of Chemistry-Revue Canadienne De Chimie},
	volume = {72},
	number = {4},
	year = {1994},
	note = {ISI Document Delivery No.: NN830Times Cited: 84Cited Reference Count: 47},
	month = {Apr},
	pages = {1005-1013},
	type = {Article},
	abstract = {Photodynamic therapy (PDT) involves the treatment of diseased tissue and cells using a photosensitizer and visible light. Such photomedical treatments have been known since the time of the ancient Egyptians but it was only just this year that this therapeutic modality was made available to modern medicine with the approval, in Canada, of Photofrin(R) for the treatment of bladder cancer. This paper reviews PDT with an emphasis on drug development, particulary for the second generation drugs, especially BPDMA (benzoporphyrin derivative-mono acid), which is now in human clinical trials.},
	keywords = {BENZOPORPHYRIN DERIVATIVES, CELLS, HEMATOPORPHYRIN, INACTIVATION, MICE, PHOTOSENSITIZATION, PLASMA-LIPOPROTEINS, porphyrins, PROTEIN DAMAGE, PROTOPORPHYRIN},
	isbn = {0008-4042},
	url = {<Go to ISI>://A1994NN83000001},
	author = {Dolphin, D.}
}
